Literature DB >> 14750638

Natural history of gastro-oesophageal reflux disease: the neglected factor.

M Bortolotti1.   

Abstract

The natural history of gastro-oesophageal reflux disease (GORD) is still a matter for research. The follow-up of GORD patients under placebo and after suspension of the drugs that healed the disease, along with observations of large patient populations treated with, or without, antisecretory drugs for long periods of time, may give some information on the spontaneous evolution of the disease. To single out the outcome of each patient, predictive factors based on demographic, morphologic and pathophysiologic characteristics have been devised, but their reliability is debatable. The reason for their many discrepancies could lie in the fact that, to date, the large majority of investigators have focused their research on the characteristics of gastro-oesophageal reflux and underlying motor activity, and have overlooked the resistance of the oesophageal mucosa. As many studies have shown that the severity of GORD is not proportional to the amount of reflux, we strongly believe that knowledge of the capacity of the mucosa to resist injury and repair the damage is the key to understanding why patients with low reflux may have severe disease, while patients with high reflux may not. Research on the kind and degree of mucosal defects in patients with GORD should receive more attention and because it may help to clarify the laws that govern the GORD evolution.

Entities:  

Mesh:

Year:  2003        PMID: 14750638     DOI: 10.1080/00365520310007008

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  1 in total

1.  Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure.

Authors:  Fabio Pace; Stefano Pallotta; Gianpiero Manes; Annalisa de Leone; Patrizia Zentilin; Luigi Russo; Vincenzo Savarino; Matteo Neri; Enzo Grossi; Rosario Cuomo
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.